June 2026 in Oncology: A Look Back at FDA Approvals and Decisions

June 2026 delivered a steady run of FDA actions across breast, prostate, and kidney cancer, continuing a year that has already reshaped frontline treatment in several tumor types. The month's headline news came in its final week, when two long-awaited approvals in triple-negative and HER2-positive breast cancer landed within a day of each other. Earlier in the month, the agency cleared new combination regimens in prostate and kidney cancer, while several other applications, carried over from earlier reviews, saw their fates decided or further delayed in the final days of June.